Investors should monitor upcoming Phase 2a initiation in 2Q 2026 and further data readouts from higher-dose cohorts. The differentiated profile vs. GLP-1s could position WVE-007 as a maintenance or combination therapy, creating significant commercial upside.
Price Chart
Executive Summary
Wave Life Sciences released positive Phase 1 data for WVE-007, an investigational obesity treatment, showing significant and durable reductions in visceral fat (-14% vs. placebo) and improved body composition six months after a single dose. The results support advancement into Phase 2a trials in higher-BMI patients in 2Q 2026 and suggest potential in MASH, type 2 diabetes, and cardiovascular disease. The therapy continues to show a favorable safety profile.
Key Facts
- Single 240 mg dose of WVE-007 led to -14.3% placebo-adjusted reduction in visceral fat at 6 months (p<0.05)
- Total fat reduced by -5.3%, waist circumference by -3.3%, body weight by -0.9%, with lean mass preserved (+2.4%)
- Visceral fat-to-muscle ratio (VMR) improved by -16.5%, outperforming semaglutide's -12.2% in a higher-BMI population
- Serum Activin E suppressed up to 88%, supporting potential for once- or twice-yearly dosing
- WVE-007 remains generally safe and well tolerated with no severe or serious treatment-related adverse events
- Phase 2a trial in patients with BMI 35-50 kg/m² expected to initiate in 2Q 2026
Financial Impact
High potential long-term revenue if WVE-007 succeeds in obesity and related metabolic diseases; competitive advantage due to muscle-preserving fat loss and infrequent dosing
Risk Factors
- Phase 1 results are in lower-BMI individuals; efficacy may not translate to higher-BMI populations in Phase 2a
- Development timeline remains long, with key data not expected until 2026-2027
- Competition from established and emerging obesity therapies is intense
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262889 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | Insider Cluster | $5.41 $4.58 | ▼ −15.34% | ▼ −13.35% | $3.81 (−29.57%) |
May 18, 2026 19w ago | Press Release | $6.14 $5.95 | ▼ −3.09% | ▼ −4.08% | $3.81 (−37.95%) |
Apr 28, 2026 22w ago | 8-K | $7.52 $6.34 | ▼ −15.69% | ▼ −21.15% | $3.81 (−49.34%) |
Apr 28, 2026 22w ago | Press Release | $7.52 $6.38 | ▼ −15.16% | ▼ −20.63% | $3.81 (−49.34%) |
Apr 22, 2026 23w ago | Press Release | $7.38 $6.14 | ▼ −16.80% | ▼ −19.97% | $3.81 (−48.37%) |
Apr 15, 2026 24w ago | DEFA14A | $7.32 $6.99 | ▼ −4.51% | ▼ −10.32% | $3.81 (−47.95%) |
Apr 15, 2026 24w ago | 8-K | $7.32 $6.99 | ▼ −4.51% | ▼ −10.32% | $3.81 (−47.95%) |
Mar 26, 2026 27w ago | Press Release | $6.20 $7.18 | ▲ +15.81% | ▲ +5.14% | $3.81 (−38.55%) |
Feb 26, 2026 31w ago | 8-K | $15.36 $6.20 | ▼ −59.64% | ▼ −53.23% | $3.81 (−75.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access